日本版NIH及其制药企业，政策制定·战略规划需要佐证。为此，本研究尝试基于新的指标体系进行制药产业的现状俯瞰与未来预测。连载第二篇，着眼于可望今后成长的生物药物，从不同的技术观点来分析各国的强项与弱项。其结果重新认识了美国在生物药物研发中的优势。同时表明，日本研发中的某些领域可以期待。%For the sake of providing evidences that contribute to policy making or strategy planning in a Japanese version of the NIH and pharmaceutical companies, we tried an overview and future prospects of pharmaceutical industry based on new indicators. Focusing on Bio-medicine which has high future growth potential, we analyzed the strengths and weaknesses of each country in each technology ifeld. Consequently, the results showed the competitive advantage of U. S. in the R&D of Bio-medicine. We also indicated the strengths of Japan in some ifeld of Biotechnology.
展开▼
